OPKO Health and Entera Bio abstract selected for ESPEN Congress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
July 8, 2025 8:00 AM EDTMIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) and Entera Bio Ltd. (NASDAQ: ENTX) (Entera) today announced that their abstract First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress, taking place September 1316, 2025, in Prague, Czech Republic.
Abstract Title: First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome
Poster Viewing Date & Time: September 13, 2025, 3:30 - 4:00 p.m. local time &... More
